Keryx Biopharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, KERX, Keryx Biopharmaceuticals Inc, priceseries

Keryx Biopharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.44
Close
3.36
High
3.46
Low
2.96
Previous Close
3.43
Daily Price Gain
-0.07
YTD High
19.86
YTD High Date
Apr 27, 2004
YTD Low
0.09
YTD Low Date
Mar 5, 2009
YTD Price Change
-6.70
YTD Gain
-66.60%
52 Week High
19.86
52 Week High Date
Apr 27, 2004
52 Week Low
0.09
52 Week Low Date
Mar 5, 2009
52 Week Price Change
-6.70
52 Week Gain
-66.60%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 6. 2017
5.03
Mar 22. 2017
5.47
12 Trading Days
8.84%
Link
LONG
Jun 21. 2017
6.33
Jul 17. 2017
7.64
17 Trading Days
20.70%
Link
LONG
Aug 22. 2017
6.74
Sep 11. 2017
7.29
13 Trading Days
8.19%
Link
LONG
Apr 9. 2018
4.19
Apr 23. 2018
4.56
10 Trading Days
8.82%
Link
LONG
May 8. 2018
4.86
May 18. 2018
5.29
8 Trading Days
8.85%
Link
Company Information
Stock Symbol
KERX
Exchange
NasdaqCM
Company URL
http://www.keryx.com
Company Phone
617-466-3500
CEO
Gregory P. Madison
Headquarters
Massachusetts
Business Address
ONE MARINA PARK DR., BOSTON, MA 02210
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001114220
About

Keryx Biopharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of renal disease. Its products include phosphate-binding medicines, intravenous iron, and other medications. The company was founded in October 1998 and is headquartered in Boston, MA.

Description

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has a license agreement with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading